Previous close | 0.0050 |
Open | 0.0030 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.0050 - 0.0050 |
52-week range | 0.0023 - 1.4000 |
Volume | |
Avg. volume | 405,811 |
Market cap | 322,366 |
Beta (5Y monthly) | 1.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8600 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Bloomios, Inc. (OTCQB: BLMS), a leading innovator in contract manufacturing of hemp-derived cannabinoid & mushroom edibles, cosmetic & topical sports products, nootropics and adjacent wellness supplements, has appointed Kevin Henry to the new position of national sales director.
Bloomios, Inc. (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, reported results for the first quarter ended March 31, 2023. All comparisons are to the same year-ago period unless otherwise noted.
Bloomios, Inc. (the "Company") (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, has appointed Upexi's former production division operations head, Joe Reid, as chief manufacturing officer of Bloomios' wholly owned subsidiary, Bloomios Private Label.